고정예산제를 활용한 외국의 약제비 관리와 시사점
Fixed Budget for Pharmaceuticals
0
조회
0
다운로드
5
인용
0
참고문헌
키워드
초록
Recently introduced PLS (positive list system) policy in Korea intends to gain cost effective in drug expenditure, by allowing reasonable prices relative to products' effectiveness. Under the increasingly constrained health budget situation, it is a reasonable policy tool to be used in any country. However, it does not allow one, as contrary to one easily hopes, to control total drug expenditure. In terms of health policy tools for drug expenditure management, if controlling drug expenditure were set as an objective of health policy in one's setting, one may need additional tools. One such tool Korea can think of under the current situation of rapidly rising drug expenditure is the fixed budget for pharmaceuticals. It would be rather a stringent policy tool from the pharmaceutical industry's point of view, but if one extends the perspective to society level, it can be considered as a reasonable option. In particular, as in Korea where pharmaceutical policy has been mostly in the form of price control, management of drug expenditure can now be extended toward quantity control as well. Fixed drug budget(FDB), in that regard, is an option open to Korea now. If FDB is considered as a possible policy option, a carefully designed impact analysis from all different angles is strongly encouraged. This is because the same policy could have different kinds and level of impacts under different health care systems. No matter what, it is about time for Korea to consider FDB as a drug policy option.
Abstract
Recently introduced PLS (positive list system) policy in Korea intends to gain cost effective in drug expenditure, by allowing reasonable prices relative to products' effectiveness. Under the increasingly constrained health budget situation, it is a reasonable policy tool to be used in any country. However, it does not allow one, as contrary to one easily hopes, to control total drug expenditure. In terms of health policy tools for drug expenditure management, if controlling drug expenditure were set as an objective of health policy in one's setting, one may need additional tools. One such tool Korea can think of under the current situation of rapidly rising drug expenditure is the fixed budget for pharmaceuticals. It would be rather a stringent policy tool from the pharmaceutical industry's point of view, but if one extends the perspective to society level, it can be considered as a reasonable option. In particular, as in Korea where pharmaceutical policy has been mostly in the form of price control, management of drug expenditure can now be extended toward quantity control as well. Fixed drug budget(FDB), in that regard, is an option open to Korea now. If FDB is considered as a possible policy option, a carefully designed impact analysis from all different angles is strongly encouraged. This is because the same policy could have different kinds and level of impacts under different health care systems. No matter what, it is about time for Korea to consider FDB as a drug policy option.
참고문헌 (22)
- 고수경, "주요국 병원의 총액예산모형과 국내적용에 대한 연구", 박사, pp.2003
- 비급여 전환 의약품의 사용현황 및 약제비 분석연구, "박혜경", 건강보험심사평가원, ~ (2007)
- "벨기에 국가질병장애보험관리국"[URL]
- 복지부 건강보험정책관, "보험약제 관련 주요 참고자료", ~ (2010)
- "프랑스 보건부"[URL]
- "필수희귀의약품 및 약가제도 관련 국외출장결과보고서(벨기에, 프랑스, 이태리)"[URL]
- 합리적 약제비 지출방안 연구, "허순임", 국민건강보험공단, ~ (2006)
- "Belgium Health System Review", Systems in Transition, 9(2) (2007)
- "Belgium, Pharmaceutical Pricing and Reimbursement Information(PPRI)", ~ (2008)
- Delnoji, M., "Importing budget systems from other countires : what can we learn from the German drug budget and the British GP fundholding", Health Policy, 52, pp.157~169 (2000)
- Drummond, M., "Moving Beyond the Drug Budget Silo Mentality in Europe", Value in Health, 6(1), pp.74~77 (2003)
- Folino, P., "Pricing and Reimbursment of pharmaceuticals in Italy", The European Journal of Health Economics, 9, pp.305~310 (2008)
- "France, Pharmaceutical Pricing and Reimbursement Information(PPRI)", ~ (2008)
- Garrison, L., "The Drug Budget Silo Mentality in Europe:an Overview", Value in Health, 6(1), pp.1~9 (2003)
- Hoffer, G., "Rationalization of Pharmaceutical Spending in Hungary(the implementation of pharmaco-economic evaluations in decision making of pricing and reimbursement of medicines)", ~ (2004)
- Koopmanschap, M., "The Drug Budget Silo Mentality : The Dutch Case", Value in Health, 6(1), pp.46~51 (2003)
- Le pen C., "The Drug Budget Silo Mentality:The French Case", Value in Health, 6(1), pp.11~19 (2003)
- Les Chiffres clés de la Sécurité sociale, "Direction de la sécurité sociale, Ministère du travail, de la solidarité et de la fonction publique; Ministère de la santé et des sports, Ministère du budget, des comptes publics et de la réforme de l'état", ~ (2009)
- Mrazek, M., "Comparative Approaches to Pharmaceutical Price Regulation in the European Union", CMJ, 43(4), pp.453~461 (2002)
- "Objéctif National des Dépenses d'Assurance Maladie. Rapport sur l'application des lois de financement de la sécurité sociale"[URL]
- "Comité Economique des produits de santé"[URL]
- Schwermann, T., "Using Disease Management and Market Reforms to Address the Adverse Economic Effects of Drug Budgets and Price and Reimbursement Regulations in Germany", Value in Health, 6(1), pp.20~30 (2003)